|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
1999-2-2
|
|
pubmed:abstractText |
Benign prostatic hyperplasia can be managed pharmacologically with alpha-1 adrenergic receptor antagonists. Agents that demonstrate selectivity for the alpha-1a receptor subtype may offer advantages in clinical applications with respect to hypotensive side effects. The N-alkylated saccharins reported here represent a new class of subtype selective alpha-1a adrenergic receptor antagonists which demonstrate potent effects on prostate function in vivo and are devoid of blood pressure side effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ADRA1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Finasteride,
http://linkedlifedata.com/resource/pubmed/chemical/Prazosin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, alpha-1,
http://linkedlifedata.com/resource/pubmed/chemical/Saccharin,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Terazosin,
http://linkedlifedata.com/resource/pubmed/chemical/tamsulosin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BergmanJ MJM,
pubmed-author:BrotenT PTP,
pubmed-author:ChangR SRS,
pubmed-author:CoNN,
pubmed-author:DiazV PVP,
pubmed-author:GuareJ PJP,
pubmed-author:HuffJ RJR,
pubmed-author:LeeH YHY,
pubmed-author:MunsonP MPM,
pubmed-author:NerenbergJ BJB,
pubmed-author:O'MalleySS,
pubmed-author:SchornT WTW,
pubmed-author:ScottA LAL,
pubmed-author:ThompsonW JWJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
22
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2467-72
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9873563-Adrenergic alpha-1 Receptor Antagonists,
pubmed-meshheading:9873563-Adrenergic alpha-Antagonists,
pubmed-meshheading:9873563-Alkylation,
pubmed-meshheading:9873563-Animals,
pubmed-meshheading:9873563-Aorta,
pubmed-meshheading:9873563-CHO Cells,
pubmed-meshheading:9873563-Cell Line,
pubmed-meshheading:9873563-Cricetinae,
pubmed-meshheading:9873563-Dogs,
pubmed-meshheading:9873563-Drug Design,
pubmed-meshheading:9873563-Finasteride,
pubmed-meshheading:9873563-Humans,
pubmed-meshheading:9873563-Male,
pubmed-meshheading:9873563-Models, Chemical,
pubmed-meshheading:9873563-Prazosin,
pubmed-meshheading:9873563-Prostate,
pubmed-meshheading:9873563-Rats,
pubmed-meshheading:9873563-Receptors, Adrenergic, alpha-1,
pubmed-meshheading:9873563-Saccharin,
pubmed-meshheading:9873563-Structure-Activity Relationship,
pubmed-meshheading:9873563-Sulfonamides
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Design and synthesis of N-alkylated saccharins as selective alpha-1a adrenergic receptor antagonists.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Merck & Co., West Point, PA 19486, USA.
|
|
pubmed:publicationType |
Journal Article,
In Vitro
|
